These results suggest that the GSK3β-dependent DSB repair pathway is activated in FHIT-deficient lung cancer cells and provide a scientific basis for the mechanism underlying GSK3β inhibitor-induced DNA damage and synthetic lethality in FHIT-deficient lung cancer cells. Here, GSK3B is linked to lung carcinoma.